As expected, the European Commission has approved Johnson & Johnson (JNJ +0.3%) unit Janssen Pharmaceutical Companies’ two-dose Ebola vaccine regimen, Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo).
In late May, the advisory group CHMP adopted a positive opinion recommending approval.
The event triggers a $10M milestone payment to licensor Bavarian Nordic A/S (OTCPK:BVNKF). Shares are up 3% in Europe.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.